Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.
The NRG Oncology Semiannual Meeting takes place from February 15 to 17, 2024, and serves as a hub where clinicians and researchers can meet and collaborate on the latest findings and practices in the oncology field.
Pedro Barata, MD, MSc, FACP, genitourinary oncology and clinical researcher, highlights NRG as "one of the most cooperative groups out there" when it comes to providing a space for oncologists to discuss questions and problems.
Here, Barata, a member of the Young Investigators Committee and Genitourinary Committee, discusses the goals and importance of the semiannual meeting.
Transcription:
0:05 | NRG, it’s one of the most important cooperative groups out there. Basically, what that means is a number of physicians and researchers get together on a regular basis and put together and try to develop concepts that ultimately will help patients. We try to answer questions that are relevant to patients, in this case diagnosed with many cancers. It’s an organization [that] has, you know, actually has the ability to get together colleagues and experts from different specialties, including radiation oncology, urology, medical, oncology, imaging, etc. Their role in helping moving science forward, you know, for the treatment of cancer, it's super, super important and has been for a long time.
0:58 | I think NRG, it's organized the way we know it for 10 years in a row, and it has been played a very important role in the management of advanced tumors, across solid tumors, but their role in in in academic research, it's fantastic.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More